IKENA ONCOLOGY INC. - COMMON STOCK

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

17 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

14 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

07 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

28 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Ikena Oncology Appoints Owen Hughes as Board Chair

19 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

28 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

22 Nov 2022 06:30:01 By Nasdaq GlobeNewswire

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

10 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

07 Nov 2022 07:48:49 By Nasdaq GlobeNewswire

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

07 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

26 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

18 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

05 Oct 2022 07:05:00 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in September 2022 Investor Conferences

06 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

11 Aug 2022 06:30:01 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

06 Jul 2022 06:00:01 By Nasdaq GlobeNewswire

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

22 Jun 2022 06:29:16 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in Spring 2022 Investor Conferences

18 May 2022 06:00:00 By Nasdaq GlobeNewswire

Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

12 May 2022 06:00:02 By Nasdaq GlobeNewswire